New antibody therapy aims to stop blistering skin disease
NCT ID NCT06900010
First seen Apr 07, 2026 · Last updated May 14, 2026 · Updated 8 times
Summary
This study tests a new drug called CM336 in 30 adults with moderate to severe autoimmune bullous disease, a condition where the immune system attacks the skin causing painful blisters. The drug targets specific immune cells to reduce this attack. The main goal is to see if the drug can lead to lasting remission without symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE BULLOUS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dermatology Hospital Affiliated to Shandong First Medical University
RECRUITINGJinan, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.